Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Source: Cofisem - Last Update: 2023-05-12
Key Executives
| Chief Executive Officer | |
| Chief Financial Officer | |
| Human Resources Director | |
| Director for Research and Development | |
| Company Secretary | |
| General Counsel |
Source: Cofisem - Last Update: 2022-07-18
Key Figures
| Millenium | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Net sales | 18,045,134 | 16,311,374 | 654,230 | 53,765 | 118,088 |
| Cost of sales | 5,073,584 | 2,311,021 | 6,460 | 0 | |
| Personnal costs | 0 | 0 | 0 | 0 | |
| Operating income | 8,824,439 | 11,741,434 | -621,453 | -487,311 | -361,313 |
| Income tax | 1,136,310 | 956,376 | 2,077 | -621 | 285 |
| Net income | 7,833,329 | 10,775,344 | -608,358 | -459,005 | -336,368 |
| Net consolidated income (Group share) | 7,833,329 | 10,775,344 | -608,358 | -459,005 | -336,368 |
| Fiscal year end | 12.22 | 12.21 | 12.2 | 12.19 | 12.18 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards |
Source: Cofisem - Last Update: 2023-05-12
Shareholder information
| Baillie Gifford & Co Limited | |
| BlackRock, Inc. | |
| Vanguard Group Inc |
Source: Cofisem - Last Update: 2023-05-12
Address
Moderna, Inc.
200 Square Technology
MA 02139 Cambridge, Massachusetts
United States
Phone number: +1 617 714 6500
Fax: +1 617 583 1998
https://investors.modernatx.com/
Source: Cofisem - Last Update: 2023-05-12
Please contact MyQuestion.Italy@euronext.com for Company Profile support.
